First cell treatment to fight the coronavirus awaits FDA approval for clinical trial

  • New Jersey-based therapeutics company Celularity is awaiting permission from the FDA to test whether a cancer treatment could be effective against COVID-19.
  • The cell therapy works by boosting the body’s early immune response in a way that could target the coronavirus.
  • The company transforms placental stem cells into one-size-fits-all “Natural Killer” cells that act as sentinels and keep the virus from replicating out of control.
  • Some researchers caution that the strategy is highly uncertain and potentially risky, but if the treatment proves safe and effective, Celularity will ramp up production quickly.
  • You will have to log in or register to view the full content.
Choose language »